{"id":"W4321077653","doi":"10.1038/s41591-022-02200-8","title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute on Alcohol Abuse and Alcoholism; Novartis Pharma; AstraZeneca; Allergan; Regeneron Pharmaceuticals; National Institutes of Health; Novo Nordisk; Virginia Commonwealth University; Eisai; Intercept Pharmaceuticals; Mallinckrodt Pharmaceuticals; Ionis Pharmaceuticals; Genentech; Boston Scientific Corporation; Valeant Pharmaceuticals International; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Amgen; NGM Biopharmaceuticals; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Placebo; Tolerability; Medicine; Internal medicine; Nonalcoholic steatohepatitis; Gastroenterology; Adverse effect; Randomized controlled trial; Farnesoid X receptor; Nonalcoholic fatty liver disease; Fatty liver; Pathology; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001389843,0.001115921,0.001844904,0.0002711233,0.0002640459,0.0006326899,0.0006729725,0.001191461,0.005579735],"category_scores_gemma":[0.001035826,0.0004493197,0.001044735,0.0002848143,0.0008376525,0.0007903716,0.0002464623,0.001590952,0.0005331704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003458183,"about_ca_system_score_gemma":0.0005765823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003635516,"about_ca_topic_score_gemma":0.0007175349,"domain_scores_codex":[0.9996151,0.0002090035,0.0000220986,0.00007251451,0.00003235009,0.00004900858],"domain_scores_gemma":[0.999556,0.0001263334,0.0001187959,0.00004293972,0.00003522867,0.0001205998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9626732,0.004571373,0.0006848139,0.0007940992,0.0005869552,0.00005907469,0.0000373787,0.0003536908,0.006643794,0.0001296567,0.0007054463,0.02276053],"study_design_scores_gemma":[0.9499782,0.04734713,0.001391087,0.00002557316,0.0001430589,0.0000336865,0.00001115294,0.0003183016,0.0002785837,0.00005928285,0.0004061259,0.000007880173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888057,0.0047357,0.0008381222,0.0005273116,0.000272682,0.002726845,0.0006446133,0.0001305589,0.001318525],"genre_scores_gemma":[0.9841123,0.003468769,0.002610412,0.001130766,0.0004053117,0.004924274,0.0009699407,0.00002856374,0.002349576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005579735,"threshold_uncertainty_score":0.01866609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03241289666123781,"score_gpt":0.3781655163415215,"score_spread":0.3457526196802837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}